Trial Profile
A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects With Chronic Hepatitis B Who Are Resistant to Lamivudine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 18 Aug 2016 Results at week 240 follow-up published in the Journal of Hepatology
- 05 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov
- 02 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.